Brittany Adler

Dr. Brittany Adler

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2010 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
ABAri E. Berman
Ari E. Berman
WCWai Yee Chan
Wai Yee Chan
ABAngela M. Brennan
Angela M. Brennan
RRReno C. Reyes
Reno C. Reyes
BABrittany Adler
Brittany Adler
RSRaymond Swanson
Raymond Swanson

1 April 2014 in Neurobiology of Aging
Verified
Journal Article
Closed access
BABrittany Adler
Brittany Adler
MYMark Yarchoan
Mark Yarchoan
HHHae Min Hwang
Hae Min Hwang
NLNatalia Louneva
Natalia Louneva
JBJeffrey A. Blair
Jeffrey A. Blair
GCGemma Casadesus
Gemma Casadesus

15 June 2018 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
BABrittany Adler
Brittany Adler
JRJames W. Russell
James W. Russell
LHLaura K. Hummers
Laura K. Hummers
ZMZsuzsanna H. McMahan
Zsuzsanna H. McMahan
Objective.: Autonomic dysfunction is a known complication of systemic sclerosis (SSc) that can affect vascular tone, gastrointestinal (GI) motility, heart rate, and blood pressure control. We sought to quantify autonomic symptom burden in SSc, and to define the characteristics of patients with SSc and autonomic dysfunction.Methods.: Patients with SSc were consecutively recruited during routine clinical visits at the Johns Hopkins Scleroderma Center and asked to complete the Composite Autonomic Symptom Score (COMPASS)-31 questionnaire, a validated tool to assess symptoms of autonomic dysfunction. We determined the relationship between various clinical and serological features of SSc and the total COMPASS-31 scores and domain-specific scores using the Student t test or Wilcoxon rank-sum test for dichotomous variables and linear regression analysis for continuous variables.Results.: The study included 104 patients with SSc who completed the COMPASS-31 questionnaire. The mean COMPASS-31 score in this cohort was 24.9 ± 15.5, higher than COMPASS-31 scores from previously published healthy controls (8.9 ± 8.7). Compared to patients with mild or absent GI disease, patients with significant GI disease had higher scores across several subdomains of the COMPASS-31, including orthostatic intolerance (median 10.0 vs 0, p = 0.006) and secretomotor dysfunction (median 6.4 vs 4.3, p = 0.03). There was also a dose-response relationship between GI disease severity and autonomic symptom burden.Conclusion.: Symptoms of autonomic dysfunction are common in SSc. Patients with more severe GI disease in SSc report more symptoms of dysautonomia across many facets of the autonomic nervous system.

21 February 2018 in Journal of Internal Medicine
Verified
Journal Article
Closed access
PDF file
BABrittany Adler
Brittany Adler
MPM. K. Pezhouh
M. K. Pezhouh
AKA. Kim
A. Kim
LLL. Luan
L. Luan
QZQ. Zhu
Q. Zhu
RARobert Anders
Robert Anders

25 January 2021 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
BABrittany Adler
Brittany Adler
FBFrancesco Boin
Francesco Boin
PWPaul J Wolters
Paul J Wolters
CBClifton O Bingham
Clifton O Bingham
ASAmi A Shah
Ami A Shah
ARAntony Rosen
Antony Rosen
Objectives Systemic sclerosis (SSc) is an autoimmune fibrotic disease affecting multiple tissues including the lung. A subset of patients with SSc with lung disease exhibit short telomeres in circulating lymphocytes, but the mechanisms underlying this observation are unclear. Methods Sera from the Johns Hopkins and University of California, San Francisco (UCSF) Scleroderma Centers were screened for autoantibodies targeting telomerase and the shelterin proteins using immunoprecipitation and ELISA. We determined the relationship between autoantibodies targeting the shelterin protein TERF1 and telomere length in peripheral leucocytes measured by qPCR and flow cytometry and fluorescent in situ hybridisation (Flow-FISH). We also explored clinical associations of these autoantibodies. Results In a subset of patients with SSc, we identified autoantibodies targeting telomerase and the shelterin proteins that were rarely present in rheumatoid arthritis, myositis and healthy controls. TERF1 autoantibodies were present in 40/442 (9.0%) patients with SSc and were associated with severe lung disease (OR 2.4, p=0.04, Fisher’s exact test) and short lymphocyte telomere length. 6/6 (100%) patients with TERF1 autoantibodies in the Hopkins cohort and 14/18 (78%) patients in the UCSF cohort had a shorter telomere length in lymphocytes or leukocytes, respectively, relative to the expected age-adjusted telomere length. TERF1 autoantibodies were present in 11/152 (7.2%) patients with idiopathic pulmonary fibrosis (IPF), a fibrotic lung disease believed to be mediated by telomere dysfunction. Conclusions Autoantibodies targeting telomere-associated proteins in a subset of patients with SSc are associated with short lymphocyte telomere length and lung disease. The specificity of these autoantibodies for SSc and IPF suggests that telomere dysfunction may have a distinct role in the pathogenesis of SSc and pulmonary fibrosis.

1 March 2011 in Urology
Verified
Journal Article
Closed access
GVGino J. Vricella
Gino J. Vricella
JHJohn R. Haaga
John R. Haaga
BABrittany Adler
Brittany Adler
DNDean Nakamoto
Dean Nakamoto
ECEdward E. Cherullo
Edward E. Cherullo
LPLee E. Ponsky
Lee E. Ponsky